• Media type: E-Book
  • Title: Thyroid Cancer : A Comprehensive Guide to Clinical Management
  • Contains: Foreword to Second Edition by E. Chester Ridgway, MD, MACP; Foreword to First Edition by Ernest L. Mazzaferri, MD, MACP; Preface; CONTENTS; Color Plates; Contributors; PART I General Consideratons I: Thyroid Cancer; 1 Anatomy and Physiology of the Thyroid Gland: Clinical Correlates to Thyroid Cancer; 2 Epidemiology of Thyroid Cancer; 3 Molecular Pathogenesis of Thyroid Cancer; 4 Molecular Aspects of Thyroid Cancer in Children; 5 Oncogenes in Thyroid Cancer; 6 Apoptosis in Thyroid Cancer; 7 Radiation-Induced Thyroid Cancer; 8 Classification of Thyroid Malignancies; 9 Staging of Thyroid Cancer
    10 Thyroid Cancer in Children and Adolescents11 Recombinant Human Thyrotropin; PART II General Considerations II: Nuclear Medicine; 12 History of the Role of Nuclear Medicine in the Thyroid Gland and its Diseases: A Personal Perspective; 13 Prophylaxis Against Radiation Exposure from Radioiodine; 14 Radioiodine Whole Body Imaging; 15 Primer and Atlas for the Interpretation of Radioiodine Whole-Body Scintigraphy; 16 False-Positive Radioiodine Scans in Thyroid Cancer; PART III The Thyroid Nodule; 17 The Thyroid Nodule: Evaluation, Risk of Malignancy, and Management
    18 Fine-Needle Aspiration: Technique19 Thyroid Nodules: Cellular and Biochemical Markers for Malignancy; 20 Radionuclide Imaging of Thyroid Nodules; 21 Ultrasonic Imaging of the Neck in Patients with Thyroid Cancer; 22 Thyroid Nodules and Cancer Risk: Surgical Management; PART IV Well Differentiated Thyroid Cancer: Papillary Carcinoma: A. Presentation; 23 Papillary Carcinoma: Clinical Aspects; 24 Surgical Approach to Papillary Carcinoma; 25 Papillary Carcinoma: Cytology and Pathology; PART IV Well-Differentiated Thyroid Cancer: B. Initial Management
    26 Prescribed Activity for Radioiodine Ablation27 Thyroid Remnant Radioiodine Ablation with Recombinant Human Thyrotropin; PART IV Well-Differentiated Thyroid Cancer: C. Surveillance; 28 Follow-Up Strategy in Papillary Thyroid Cancer; 29 Levothyroxine Therapy and Thyrotropin Suppression; 30 Thyroglobulin and Thyroglobulin Antibodies: Measurement and Interferences; 31 Diagnosis of Recurrent Thyroid Cancer in Patients with Antithyroglobulin Antibodies; 32 Surveillance Radioiodine Whole-Body Scans; 33 Radionuclide Imaging and Treatment of Thyroid Cancer in Children
    34 Positron Emission Tomography in Well-Differentiated Thyroid Cancer35 Alternative Thyroid Imaging; 36 The ""Stunning"" Controversy; A. Stunning: Untoward Effect of 131 I Thyroid Imaging Prior to Radioablation Therapy; B. Stunning Is Not a Problem; C. Stunning: Does It Exist? A Commentary; 37 Ultrasonic Imaging and Identification of Metastases in Cervical Lymph Nodes; 38 Magnetic Resonance Imaging and Computed Tomography of Thyroid Cancer; 39 Management of the Patients with Negative Radioiodine Scan and Elevated Serum Thyroglobulin; 40 Determinants of Prognosis in Papillary Thyroid Cancer
    41 Papillary Cancer: Special Aspects in Children
  • Contributor: Wartofsky, Leonard [Other]; Nostrand, Douglas [Other]
  • imprint: Totowa, NJ: Humana Press Inc, 2006
  • Published in: SpringerLink ; Bücher
  • Issue: Second Edition
  • Extent: Online-Ressource (digital)
  • Language: English
  • DOI: 10.1007/978-1-59259-995-0
  • ISBN: 9781592599950
  • Identifier:
  • RVK notation: XH 6265 : Therapie (medikamentöse, physikalische Rehabilitation)
  • Keywords: Schilddrüsenkrebs > Therapie
  • Origination:
  • Footnote: Includes bibliographical references (p. 683) and index
  • Description: This massive revision of the highly acclaimed first edition presents a wealth of new information and insights on every aspect of the etiology, pathogenesis, diagnosis, initial treatment, and long-term management of all varieties of thyroid cancer. Paramount is a thorough treatment of the nuclear medical aspects of diagnosing and managing the thyroid cancer patient. This includes extensive discussion of isotopes, isotope uptake and scanning procedures, radioisodine ablation and dosimetry (with or without recombinant human TSH), stunning, octreotide and FDG-PET scanning, and various alternative imaging modalities. Additional highlights include management of the scan negative and thyroglobulin-positive patient, ultrasound of the lymph nodes, local adjuncts to therapy of metastases, low iodine diets and cookbooks, future directions in therapy, and alternative therapies when traditional surgery and radioactive iodine fail.